MPP dihydrochloride
CAS No. 911295-24-4
MPP dihydrochloride ( —— )
Catalog No. M29650 CAS No. 911295-24-4
MPP dihydrochloride is a potent and selective ER (estrogen receptor) modulator. MPP dihydrochloride induces significant apoptosis in the endometrial cancer and oLE cell lines.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 886 | In Stock |
|
| 50MG | 1206 | In Stock |
|
| 100MG | 1798 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
Biological Information
-
Product NameMPP dihydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionMPP dihydrochloride is a potent and selective ER (estrogen receptor) modulator. MPP dihydrochloride induces significant apoptosis in the endometrial cancer and oLE cell lines.
-
DescriptionMPP dihydrochloride is a potent and selective ER (estrogen receptor) modulator. MPP dihydrochloride induces significant apoptosis in the endometrial cancer and oLE cell lines. MPP dihydrochloride reverses the positive effects of beta-estradiol. MPP dihydrochloride has mixed agonist/antagonist action on murine uterine ERalpha in vivo.MPP (1, 5, 10, 25, 50 and 100 μM; 24 h) decreases cell viability with an IC50 value of 20.01 μM in RL95-2 cells.MPP dihydrochloride shows antiproliferative activity at a concentration of 10 μM in RL95-2 cells.MPP dihydrochloride (20 μM; 24 h) reduces the phosphorylation of ERα, while it does not alter the phosphorylation of Akt. MPP dihydrochloride reduces the ratio of p-ERα/ERα.
-
In VitroCell Viability Assay Cell Line:RL95-2 endometrium cancer cellsConcentration:1, 5, 10, 25, 50 and 100 μM Incubation Time:24 hours Result:The treatment with 25 μM, 50 μM and 100 μM for 24 h decreased cell viability significantly. However, cell viability was not significantly changed by MPP dihydrochloride at concentration below 25 μM.Cell Proliferation Assay Cell Line:RL95-2 cell Concentration:10, 15, 20 and 25 μM Incubation Time:72 hours Result:Showed antiproliferative activity at a concentration of 10 μM.Western Blot Analysis Cell Line:RL95-2 cell line Concentration:20 μMIncubation Time:24 hours Result:Reduced the phosphorylation of ERα, while it did not alter the phosphorylation of Akt. Reduced the ratio of p-ERα/ERα compared to the control group.
-
In VivoAnimal Model:Male C57BL/6N mice at the age of 9-10 weeksDosage:Low dose (20 μg/kg body weight) or high dose (200 μg/kg body weight) Administration:Administered subcutaneously (s.c.) injected; injection volume of 5 mL/kg; 60 min before PPI testing Result:Led to a dose-dependent attenuation of percent PPI. Pretreatment with 200 μg/kg reduced the mean percent PPI scores by ~30%.
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetEstrogen Receptor/ERR
-
RecptorEstrogen Receptor/ERR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number911295-24-4
-
Formula Weight542.5
-
Molecular FormulaC29H33Cl2N3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO : 30 mg/mL (55.30 mM; Need ultrasonic and warming)
-
SMILESOC1=CC=C(C2=NN(C3=CC=C(O)C=C3)C(C4=CC=C(OCCN5CCCCC5)C=C4)=C2C)C=C1.[H]Cl.[H]Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Karabo?a Arslan AK, et al. α-Chaconine and α-Solanine Inhibit RL95-2 Endometrium Cancer Cell Proliferation by Reducing Expression of Akt (Ser473) and ERα (Ser167). Nutrients. 2018 May 25;10(6). pii: E672.
2. Labouesse MA, et al. Effects of selective estrogen receptor alpha and beta modulators on prepulse inhibition in male mice. Psychopharmacology (Berl). 2015 Aug;232(16):2981-94.
molnova catalog
related products
-
Camizestrant
Camizestrant (Estrogen receptor antagonist 2) is an antagonist of the estrogen receptor and can be used in studies about ER+ HER2-advanced breast cancer.
-
lutidinic acid
2, 4-Pyridinedicarboxylic acid is an in vitro and in cell inhibitor, as well as a known inhibitor of the histone lysine demethylases.
-
Enclomiphene citrate
Enclomiphene citrate((E)-Clomifene, cis-Clomifene, RMI-16289, ICI-46476)?is a nonsteroidal selective estrogen receptor modulator (SERM) that is under development for the treatment of male hypogonadism.
Cart
sales@molnova.com